Trial Profile
Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2018
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2014 New trial record